Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock

Walters Group, a major shareholder and director of Zentalis Pharmaceuticals Inc., has bolstered its stake in the company by acquiring $15.17 million worth of its common stock. The transaction, completed on August 14, 2026, involved the purchase of 4,335,000 shares at $3.50 per share. Currently trading at $3.83, the stock has seen a modest gain since the acquisition. Over the past year, the stock has provided a 140% return despite a 10.96% decline over the past week.

This acquisition brings Walters Group's total beneficial ownership of Zentalis Pharmaceuticals to 17,844,973 shares, directly held by The Walters Group (TWG). William T. Walters and Susan B. Walters, the general partner and majority member of TWG, may share voting and dispositive power over these shares. However, they have disclaimed beneficial ownership for Section 16 purposes, except for their financial interest.

InvestingPro analysis suggests that Zentalis is undervalued at its current price, with 13 additional ProTips available to subscribers. Zentalis Pharmaceuticals has announced an underwritten public stock offering, giving underwriters a 30-day option to acquire an additional 15% of shares. Rodman & Renshaw has initiated coverage on Zentalis with a buy rating, recognizing the commercial potential of their drug candidate, azenosertib, for ovarian cancer.

Mizuho has also joined in, assigning an Outperform rating, emphasizing the favorable risk-reward ahead of a crucial Phase 2 study expected by year-end 2026. H.C. Wainwright has maintained its Buy rating following the release of Phase 1b clinical trial data for azenosertib.

Furthermore, Zentalis Pharmaceuticals has appointed Shannon Campbell to its board of directors and Sarah Kelly as its senior vice president of commercial strategy. These appointments come as the company prepares for the potential commercialization of its ovarian cancer treatment. This report, AI-supported and editor-reviewed, provides a comprehensive overview of the recent developments at Zentalis Pharmaceuticals.